电针刺激对神经干细胞移植治疗脊髓损伤大鼠后肢功能的影响

背景：单纯的神经干细胞移植对受损脊髓组织的修复作用并不理想,为了进一步提高移植细胞在体内的存活、增殖及定向分化为神经元的比例,必须进一步改善脊髓损伤区的微环境。 目的：观察神经干细胞移植联合电针刺激对脊髓损伤大鼠后肢功能及电生理的影响。 方法：将脊髓损伤模型SD大鼠72只按随机数字表法分为4组：对照组尾静脉注入培养液,神经干细胞组经尾静脉注入等体积神经干细胞悬液,电针刺激组自模型完成6 h起采用督脉加体穴电针1周,联合组尾静脉注射神经干细胞后,同时采用督脉加体穴电针1周。分别于造模前、造模后1,3 d、1-4 周通过BBB评分、斜板试验进行运动功能评定。造模后4周取材行病理切片苏木精-伊红染色,荧光显微镜观测CM-Dil 标记的神经干细胞存活及分布情况,辣根过氧化物酶示踪观察神经纤维再生情况,运动诱发电位和体感诱发电位观察大鼠神经电生理恢复情况。 结果与结论：造模后2-4周大鼠下肢运动功能评价联合组优于神经干细胞组及电针刺激组,神经干细胞组和电针刺激组优于对照组。造模后4周,神经干细胞组和电针刺激组损伤区可见少量神经轴索样结构,脊髓空洞较小,联合组可见较多神经轴索样结构,未见脊髓空洞。造模后4周,CM-Dil 阳性细胞和辣根过氧化物酶阳性神经纤维数：联合组>神经干细胞组与电针刺激组>对照组,各组之间差异有显著性意义(P < 0.05)。运动诱发电位和体感诱发电位的潜伏期：联合组<神经干细胞组与电针刺激组<对照组,各组之间差异有显著性意义(P < 0.05);运动诱发电位和体感诱发电位的波幅：联合组>神经干细胞组与电针刺激组>对照组,各组之间差异有显著性意义(P < 0.05)。结果提示神经干细胞移植的同时联合电针刺激能够促进脊髓损伤大鼠神经突触的再生,改善其大鼠肢体运动功能及电生理功能。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程      

骨髓间充质干细胞移植脊髓全横断模型大鼠运动和体感诱发电位的评价

背景：临床常用皮质运动诱发电位和皮质体感诱发电位来分别评价脊髓损伤后运动传导路和感觉传导路的损伤或修复情况。 目的：以脊髓诱导电位监测骨髓间充质干细胞移植后急性脊髓完全性损伤大鼠下肢神经功能的变化。 方法：选取健康Wistar大鼠50只,分成5组,即生理盐水组、骨髓间充质干细胞移植组、脑源性神经营养因子修饰组、神经营养素3+骨髓间充质干细胞移植组和假手术组。除假手术组外,其余各组均制作Allen’s脊髓完全性损伤动物模型,造模后各组均行相应治疗。治疗后4,8和12周行大鼠后肢运动功能评分,并于造模后24 h,3,7,14 d行运动和体感诱发电位检测。 结果与结论：运动诱发电位检测结果提示,各治疗组的运动功能均有不同程度的恢复,与生理盐水组间差异均有显著性意义(P < 0.05),大鼠后肢BBB评分也证实了各治疗组后肢运动功能明显优于生理盐水组(P < 0.05)。提示经脑源性神经营养因子修饰的骨髓间充质干细胞可移植到脊髓损伤处,可改善大鼠的后肢运动,神经营养素3蛋白有可能提高骨髓间充质干细胞在体内的生存率,促进受损脊髓的轴突再生。     

骨髓间充质干细胞移植联合吡拉西坦修复大鼠脊髓损伤

背景：单纯的干细胞移植对脊髓损伤的修复作用并不理想,主要是因为脊髓损伤后损伤区域神经组织的水肿、缺血、缺氧等引起继发性损伤造成的。 目的：在骨髓间充质干细胞移植治疗大鼠脊髓损伤的同时应用吡拉西坦,观察两者对大鼠脊髓损伤恢复的影响。 方法：雌性Wistar大鼠参照改良Allen打击法制备大鼠脊髓损伤模型。随机分成3组,即单纯损伤组、骨髓间充质干细胞移植组及骨髓间充质干细胞移植联合吡拉西坦组。于伤后1,2,4,6,8周进行BBB评分和斜板实验等运动功能检测。第4周取材行病理切片苏木精-伊红染色,通过SRY-PCR检测雄性大鼠Y染色体上特有的基因SRY,从而得知移植骨髓间充质干细胞是否存活。8周后取材,行辣根过氧化物酶示踪观察,并通过透射电镜观察轴突的再生情况。 结果与结论：伤后4周,骨髓间充质干细胞移植组、联合治疗组大鼠后肢运动功能均有较明显恢复,联合治疗组较骨髓间充质干细胞移植组恢复快(P < 0.05)。单纯损伤组亦有所恢复,但程度较轻。病理切片单纯损伤组未见神经轴索通过;骨髓间充质干细胞移植组可见少量神经轴索样结构;联合治疗组可见较多神经轴索样结构。骨髓间充质干细胞移植组、联合治疗组有SRY基因表达,单纯损伤组未检测到SRY基因。辣根过氧化物酶阳性神经纤维数联合治疗组﹥骨髓间充质干细胞移植组>单纯损伤组,差异具有显著性意义(P < 0.05)。透射电镜下,骨髓间充质干细胞移植组、联合治疗组正中横断面可见新生的无髓及有髓神经纤维。提示骨髓间充质干细胞移植联合吡拉西坦促进大鼠损伤脊髓结构和功能恢复的效果明显优于单纯细胞移植组,两者联用具有协同效应。     

高压氧联合神经干细胞移植治疗大鼠脊髓损伤

背景：单纯神经干细胞移植已应用于对受损脊髓组织的修复。 目的：以神经干细胞移植同时应用高压氧治疗大鼠脊髓损伤,观察联合作用对脊髓损伤大鼠运动功能恢复的影响。 方法：雌性SD大鼠60只,以半切法制成胸段脊髓半横断大鼠模型。随机分成单纯损伤组、神经干细胞移植组及高压氧治疗组,每组20只。伤后第4周取材行病理切片苏木精-伊红染色及BrdU免疫组织化学染色,第8周取材行辣根过氧化物酶示踪,透射电镜观察轴突的再生情况,通过体感诱发电位观察神经电生理恢复情况。造模后1,2,4,6,8周进行BBB评分和斜板实验等运动功能检测。  结果与结论：观察伤后4周病理切片,单纯损伤组未见神经轴索通过,神经干细胞移植组可见少量神经轴索样结构,高压氧治疗组可见较多神经轴索样结构。BrdU的阳性细胞数及辣根过氧化物酶阳性神经纤维数,高压氧治疗组最多,神经干细胞移植组次之,单纯损伤组最少,且各组之间差异有显著性意义(P < 0.05)。透射电镜下神经干细胞移植组、高压氧治疗组正中横断面可见新生的无髓及有髓神经纤维。高压氧治疗组大鼠体感诱发电位的潜伏期短于神经干细胞移植组,波幅高于神经干细胞移植组(P < 0.05),明显优于单纯损伤组(P < 0.01)。伤后4周神经干细胞移植组、高压氧治疗组大鼠后肢运动功能均有较明显恢复,高压氧治疗组较神经干细胞移植组恢复快(P < 0.05);单纯损伤组亦有所恢复,但程度较轻。提示神经干细胞移植对于脊髓损伤大鼠后肢功能的恢复有促进作用,联合应用高压氧有协同效果。     

低频电磁场促进骨髓间充质干细胞移植修复大鼠脊髓损伤的实验研究

背景：骨髓间充质干细胞移植治疗脊髓损伤被视为一种有前途的治疗方法,如何更有效地促进骨髓间充质干细胞在脊髓损伤区存活,加速脊髓损伤肢体运动功能的恢复是目前研究的重点。前期研究发现,低频电磁场能够促进骨髓间充质干细胞的增殖分化,低频电磁场是否可应用于骨髓间充质干细胞移植治疗脊髓损伤还需进一步研究。 目的：探讨低频电磁场对移植骨髓间充质干细胞脊髓损伤大鼠后肢运动功能恢复的影响。 方法：采用脊髓压迫法制备64只T10不完全性脊髓损伤大鼠模型,随机等分为对照组、骨髓间充质干细胞组、电磁场组和电磁场+骨髓间充质干细胞组。造模成功后,骨髓间充质干细胞组和电磁场+骨髓间充质干细胞组大鼠脊髓损伤原部位注射大鼠全贴壁法分离培养BrdU标记的骨髓间充质干细胞,对照组和电磁场组注射a-MEM培养液。造模术后24 h,电磁场组和电磁场+骨髓间充质干细胞组予60 min/d的低频电磁场刺激(频率50 Hz、强度5 mT)。 结果与结论：骨髓间充质干细胞移植后第21天,电磁场+骨髓间充质干细胞组BBB评分与其他组相比,差异有显著性意义(P < 0.05),与其他各组比较,电磁场+骨髓间充质干细胞组移植细胞后,大鼠BrdU阳性细胞在脊髓损伤区域生长并与脊髓组织融合,存活细胞数量较其他组多;空洞面积小;损伤区胶质纤维酸性蛋白表达更少,而基质金属蛋白2表达更多;脊髓损伤大鼠下肢运动功能恢复最快(P < 0.05)。提示低频电磁场促进了移植骨髓间充质干细胞脊髓损伤大鼠后肢运动功能的恢复,可能与低频电磁场有利于损伤区移植骨髓间充质干细胞的存活,上调基质金属蛋白2的表达并减少胶质瘢痕的形成有关。     

骨髓间充质干细胞静脉移植治疗大鼠脊髓损伤

背景：干细胞移植可以重建中枢神经系统的结构和功能,近年来引起了广泛的关注。 目的：尾静脉移植骨髓间充质干细胞观察其对大鼠脊髓损伤修复的影响并探讨其机制。 方法：密度梯度离心法结合贴壁筛选法分离骨髓间充质干细胞。将成年雌性Wistar大鼠以动脉瘤夹钳夹法制备大鼠脊髓损伤模型后随机分为细胞移植组和对照组,分别干预。 结果与结论：细胞移植组大鼠BBB后肢功能评分恢复优于对照组(P < 0.05)。自损伤后第30天开始,细胞移植组大鼠运动诱发电位潜伏期及体感诱发电位P1波潜伏期的恢复均优于对照组(P < 0.05),并持续至实验结束。细胞移植组大鼠脊髓内在损伤中心及头、尾端距离脊髓损伤中心1 cm处均可见阳性细胞。说明尾静脉注射移植骨髓间充质干细胞可以促进脊髓损伤大鼠神经功能恢复,其机制可能与移植细胞迁移到损伤部位,分化为神经元样和神经胶质细胞样细胞,并分泌或促进宿主分泌神经营养因子有关。     

乌司他丁联合脐带间充质干细胞移植脊髓损伤大鼠后肢运动功能和 运动诱发电位的变化

背景：乌司他丁能减轻炎性反应、清除氧自由基,对中枢神经系统损伤具有保护作用,能有效地提高脊髓损伤后移植细胞的存活率。 目的：观察乌司他丁联合脐带间充质干细胞移植对脊髓损伤大鼠后肢功能的影响。 方法：Wistar大鼠建立脊髓损伤动物模型后随机分成4组：空白对照组尾静脉注射培养液+腹腔注射生理盐水,细胞移植组尾静脉注射脐带间充质干细胞,乌司他丁组腹腔注入乌司他丁,联合组尾静脉注射脐带间充质干细胞,同时腹腔注入乌司他丁。 结果与结论：移植4周后联合组下肢运动功能优于细胞移植组和乌司他丁组(P < 0.05),细胞移植组和乌司他丁组优于空白对照组(P < 0.05)。移植后4周,PKH26标记的阳性细胞数联合移植组多于细胞移植组,细胞移植组多于乌司他丁组和空白对照组(P < 0.01)。移植后8周,联合组大鼠体感诱发电位及运动诱发电位的潜伏期、波幅明显优于其他3组(P < 0.05或P < 0.01)。提示乌司他丁联合应用脐带间充质干细胞移植可促进脊髓损伤大鼠神经突触的再生,改善其肢体运动功能和电生理功能,其效果优于单独应用乌司他丁或脐带间充质干细胞。     

控释胶质细胞源性神经营养因子与骨髓间充质干细胞源神经元样细胞移植可减少脊髓损伤后空洞形成

背景：前期研究发现控释胶质细胞源性神经营养因子与骨髓间充质干细胞源神经元样细胞移植可以有效地促进猕猴脊髓损伤后运动功能的恢复。 目的：验证控释胶质细胞源性神经营养因子联合骨髓间充质干细胞源神经元样细胞移植对猴脊髓损伤后组织结构的保护作用是否优于单纯细胞移植。 方法：将急性重度脊髓损伤模型恒河猴分为3组,联合移植组采用控释神经营养因子+神经元样细胞联合移植,单纯细胞移植组给予神经元样细胞移植,对照组给予磷酸盐缓冲液。制备脊髓组织石蜡标本,苏木精-伊红染色后显微镜下观察空洞形成情况,并应用图像分析系统计算空洞面积。 结果与结论：对照组脊髓结构严重破坏,空洞面积大、累及范围广;单纯细胞移植组脊髓结构保存较好,有小面积空洞,偶有较大空洞形成;联合移植组脊髓结构保存最好,仅存在小面积空洞。组间两两比较差异有显著意义(P < 0.01)。提示与单纯神经元样细胞移植比较,控释胶质细胞源性神经营养因子联合骨髓间充质干细胞源性神经元样细胞移植对脊髓损伤后组织结构的保护作用更佳,可以在更大程度上减少脊髓空洞的形成可能是其作用机制之一。     

口服肉苁蓉联合骨髓间充质干细胞移植治疗大鼠脊髓损伤

背景:研究表明骨髓间充质干细胞在特定的条件下可分化成为神经细胞,移植后可重建神经系统功能,改善患者功能障碍,肉苁蓉总苷也对损伤的神经细胞有保护作用,将二者联合应用的报道较少。目的:探讨口服肉苁蓉联合骨髓间充质干细胞移植修复大鼠脊髓损伤的效果。方法:55只成年Wistar大鼠制备脊髓损伤模型,随机分为4组,对照组每天20 mL/kg生理盐水灌胃;口服肉苁蓉组每天20 mL/kg肉苁蓉条件浓缩液灌胃;骨髓间充质干细胞移植组造模后即刻移植骨髓间充质干细胞悬液(1×108 L-1)10μL,每天20 mL/kg生理盐水灌胃;口服肉苁蓉+骨髓间充质干细胞移植组造模后即刻移植骨髓间充质干细胞悬液(1×108 L-1)10μL,每天20 mL/kg肉苁蓉条件浓缩液灌胃,各组连续灌胃30 d。结果与结论:治疗30 d后免疫组化法检测口服肉苁蓉+骨髓间充质干细胞移植组脊髓组织中Nestin阳性表达明显多于其他组;治疗12周后,口服肉苁蓉+骨髓间充质干细胞移植组BBB评分明显高于其他组,差异有显著性意义(P0.05),感觉诱发电位和运动诱发电位潜伏期较其他组有明显改善(P0.05)。结果表明口服肉苁蓉联合骨髓间充质干细胞移植可以明显改善脊髓损伤大鼠的运动功能及神经电生理功能;口服肉苁蓉可以有效促进移植的骨髓间充质干细胞在宿主内存活。     

高压氧联合许旺细胞移植脊髓损伤大鼠电生理及后肢功能的变化

背景：高压氧治疗可以改善脊髓损伤区微环境,联合许旺细胞移植有望提高大鼠脊髓损伤疗效。目的：观察高压氧联合许旺细胞移植对脊髓损伤大鼠神经功能恢复的影响。方法：80只雌性SD大鼠建立脊髓损伤模型后随机分成4组,每组20只,空白对照组和细胞移植组分别在建模6 h后尾静脉注射L-DMEM培养液和许旺细胞(3×10⁶个)悬液,高压氧组建模1 h后开始高压氧治疗,联合组进行高压氧和许旺细胞移植联合治疗。于移植后1,3 d以及1,2,3,4周进行斜板试验、改良Tarlov 评分,BBB评分评定大鼠后肢运动功能恢复情况;移植第4周PCR检测各组脊髓组织中SRY基因表达;移植第8周行辣根过氧化物酶示踪及神经电生理检测。结果与结论：联合组下肢运动功能优于细胞移植组和高压氧组,细胞移植组和高压氧组优于空白对照组。细胞移植组和联合组有SRY基因表达,对照组和高压氧组未检测到SRY基因。辣根过氧化物酶阳性神经纤维数：联合组>细胞移植组和高压氧组>空白对照组,差异有显著性意义(P < 0.01)。联合组大鼠体感诱发电位及运动诱发电位的潜伏期、波幅明显优于其他3组(P < 0.05或P < 0.01)。结果提示高压氧与许旺细胞移植联合应用可促进脊髓损伤大鼠神经突触的再生,改善肢体运动功能和电生理功能,其治疗效果优于单独应用高压氧或许旺细胞。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma

Background: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental. Objective: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma. Methods: This was a randomized, double-blind, parallel-group trial. Three hundred sixty-two patients 12 years of age or older were treated with study drug administered by means of nebulization 3 times daily for 28 days. The primary endpoint was peak change in FEV₁ after 4 weeks. Results: The change in peak FEV₁ response to the first dose in the combined levalbuterol group was significantly greater compared with the combined racemic albuterol group (0.92 and 0.82 L, respectively; P = .03), with similar but nonsignificant results after 4 weeks (0.84 and 0.74 L, respectively). Improvement in FEV₁ was similar for levalbuterol 0.63 mg and racemic albuterol 2.5 mg and greatest for levalbuterol 1.25 mg. Racemic albuterol 1.25 mg demonstrated the weakest bronchodilator effect, particularly after chronic dosing. The greatest increase in FEV₁ was seen after levalbuterol 1.25 mg, especially in subjects with severe asthma. All active treatments were well tolerated, and β-adrenergic side effects after administration of levalbuterol 0.63 mg were reduced relative to levalbuterol 1.25 mg or racemic albuterol 2.5 mg. At week 4, the predose FEV₁ value was greatest in patients who received levalbuterol or placebo when compared with those who received racemic albuterol. The difference was more evident and was statistically significant in patients who were not receiving inhaled corticosteroids. Conclusion: Levalbuterol appears to provide a better therapeutic index than the standard dose of racemic albuterol. These results support the concept that (S)-albuterol may have detrimental effects on pulmonary function. (J Allergy Clin Immunol 1998;102:943-52.)     

Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab

Background: The use of rituximab (RTX) is increasing, even in developing countries. It has become the first-line therapy or adjuvant to chemotherapy (CHOP; cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) for various diseases, including B cell lymphoma and autoimmune diseases.

Aim: We describe the infectious diseases and immunological markers associated with RTX treatment of patients with non-Hodgkin lymphoma (NHL).

Methods: Serum immunoglobulins were determined before and after intravenous immunoglobulin (IVIg) administration. Pneumo-23IgG-specific anti-pneumococcal antibodies were evaluated before and after vaccination. Immunophenotyping and lymphocyte proliferation were determined in the course of the treatment.

Results: Seven patients were followed and median age was 56.0?±?5.0?years (range, 41.9–71.6?years). At baseline, the mean level of IgG was 333.7?±?40.8?and IgM 40.9?±?11.3?mg/dL, respectively; immunoglobulin A and E (IgA and IgE) were under the limit of detection. Two patients had reduced or absent B cells and T cell subsets were at normal levels in five patients. All patients failed to mount an efficient post-vaccination immune response against hepatitis B virus, tetanus, diphtheria and against the 23-valent pneumococcal polysaccharide vaccine. During RTX/CHOP treatment, human-IgG-immunoglobulin (IVIg) therapy was introduced in six patients after recurrent infections, including community-acquired pneumonia (85.7%), chronic sinusitis (85.7%) and gastroenteritis (42.9%).

Conclusion: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections.     

Establishing Safety with Patients with Dissociative Identity Disorder

Abstract

The incidence of self-mutilation and suicidality among patients with dissociative disorders is quite high. It is necessary for clinicians working with this population to be adept at dealing with safety problems. This article presents a sequence of basic steps that can be used when helping dissociative patients establish safety, a discussion of the functions of self-destructiveness, and an overview of specific experiences and thinking patterns that contribute to self-destructiveness among dissociative patients.     

VACTERL with hydrocephalus: Family with X-linked VACTERL-H

We describe in a five generation family four affected males with hydrocephalus (4 offspring/4 examined) due to aqueductal stenosis (3/3), symmetrical radial ray abnormalities (4/4), renal anomalies (2/3), anal atresia (3/4), hypoplastic penis/abnormal testes (2/3), and cardiac abnormalities (1/3). X-linked inheritance seems certain in this family. These abnormalities are characteristic of the rare X-linked VACTERL-H syndrome. In addition, one maternal female cousin had a severe tracheo-esophageal fistula. This may represent partial manifestation in a female carrier. Chromosomes were apparently normal (46XY) with no spontaneous or excess induced breakages in one of the affected offspring and his mother. In the absence of a genetic marker, diagnostic ultrasonography is the investigation of choice for early in utero detection of this syndrome. A confident ultrasonographic diagnosis was possible by 20 weeks in the 2 cases examined. Am. J. Med. Genet. 76:74–78, 1998. © 1998 Wiley-Liss, Inc.     

拉米夫定与泛昔洛韦联合治疗乙型肝炎病毒慢性感染的临床研究

目的 观察拉米夫定与泛昔洛韦联合治疗乙型肝炎病毒(HBV)慢性感染的临床疗效。方法 慢性乙型肝炎患者90例。设联合治疗组28例，单用拉米夫定组30例，单用泛昔洛韦组32例。联合治疗组给予口服拉米夫定0．1g／d(PO)，泛昔洛韦1．5g／d(PO)，24周。拉米夫定、泛昔洛韦单用组剂量及疗程分别同联合治疗组。结果 3组均无明显副反应，丙氨酸转氨酶(ALT)复常率无差异。3组HBV DNA阴转率分别为89．3％、66．7％、40．6％，差异有显著性。乙型肝炎表面抗原(HBeAg)阴转率分别为28．6％、23．3％、21．9％，差异无显著性。结论 拉米夫定与泛昔洛韦联合用药安全、耐受性好，临床显示联合治疗对HBV DNA的抑制作用显著优于单用药。     

Intervention with epinephrine in hypotension associated with mastocytosis

The occurrence of the episodes of vasodilatory hypotension can be a life-threatening manifestation of systemic mastocytosis. This article describes the reversal by epinephrine of episodes of severe hypotension in two hospitalized patients with mastocytosis. Recognition of the efficacy of epinephrine in hypotension associated with mastocytosis can be important when other methods fail to restore hemodynamic stability.